Histone deacetylase inhibitor for NUT midline carcinoma

Pediatric Blood and Cancer

Volumn 62, Issue 4, 2015, Pages 715-717

  Maher, Ossama M ^a   Christensen, Anthony M ^b   Yedururi, Sireesha ^a   Bell, Diana ^a   Tarek, Nidale ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Histone deacetylase inhibitor; NUT midline carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; NUCLEAR PROTEIN; TESTIS NUCLEAR PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ADOLESCENT; ANEMIA; ARTICLE; BONE MARROW BIOPSY; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER SIZE; CASE REPORT; COMPRESSION FRACTURE; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE COURSE; DRUG DOSE REDUCTION; DYSPNEA; FEMALE; FEVER; HEMATOTHORAX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRACTABLE PAIN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NUCLEAR PROTEIN OF THE TESTIS MIDLINE CARCINOMA; PLEURA EFFUSION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA; WEIGHT REDUCTION; CARCINOMA; MANDIBULAR NEOPLASMS; METASTASIS; PATHOLOGY; PLEURAL EFFUSION, MALIGNANT;

ADOLESCENT; CARCINOMA; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MANDIBULAR NEOPLASMS; NEOPLASM METASTASIS; PLEURAL EFFUSION, MALIGNANT;

EID: 84923170142     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25350     Document Type: Article

References (15)

1. Kubonishi I, Takehara N, Iwata J, Sonobe H, Ohtsuki Y, Abe T, Miyoshi I. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 1991; 51:3327-3328.
2. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7:247-265.
3. French CA. The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 2013; 7:11-16.
4. Stelow EB. A review of NUT midline carcinoma. Head Neck Pathol 2011; 5:31-35.
5. Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, Stelow EB, Hong SM, Schwartz BE, Cameron MJ, Rubin MA, Chang MC, Aster JC, French CA. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009; 33:984-991.
6. Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012; 36:1222-1227.
7. French CA. NUT midline carcinoma. Cancer Genet Cytogenet 2010; 203:16-20.
8. Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Luer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, Giraldi E, Oakley RP, Rodriguez-Galindo C, London WB, Sallan SE, Bradner JE, French CA. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012; 18:5773-5779.
9. French CA, Kutok JL, Faquin WC, Toretsky JA, Antonescu CR, Griffin CA, Nose V, Vargeas SO, Moschovi M, Tzortzatou-Stathopoulou F, Miyoshi I, Perez-Atayde AR, Aster JC, Fletcher JA. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004; 22:4135-4139.
10. Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, French CA. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 2011; 71:2686-2696.
11. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thanque N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Selective inhibition of BET bromodomains. Nature 2010; 468:1067-1073.
12. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006; 5:1967-1974.
13. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010; 11:459-464.
14. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid J, McGovern RM, Ames MM, Gilberston RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer 2013; 60:1452-1457.
15. Fouladi M, Park J, Stewart CF, Gilberston RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28:3623-3629.